Refine your search

Clear

Search Results

Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.

1 Study Matches

Interventional, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multi-centre Study to Assess the Efficacy, Safety and Tolerability of Lu AF82422 in Patients with Multiple System Atrophy (MSA)

18331A (AMULET - Delay Multiple System Atrophy) is a Phase 2, placebo-controlled trial designed to assess the efficacy, safety and tolerability of Lu AF82422 in subjects with MSA MSA-C or MSA-P). The study is planned to consist of a screening period of 4 weeks, a randomization period of 2 weeks and a double-blind treatment period of 48 to 72 weeks . Approximately 60 subjects are planned to be randomized in a 2:1 ratio to receive either Drug A, or placebo.
Michael Klemick at TBRC@pennstatehealth.psu.edu or 717-531-5233
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT05104476
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Multiple System Atrophy
Age >=40 and <=75 at screening
Exclusion Criteria:
Pregnant or breastfeeding
Unable to have MRI
Neurology
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA